Home › Myelodysplastic Syndromes
Myelodysplastic Syndromes clinical trials recruiting in the U.S.
158 studies for Myelodysplastic Syndromes are recruiting participants at sites across the United States.
Myelodysplastic Syndromes (MDS) are rare. They are sometimes found during a routine blood test. Learn symptoms, risk factors, and treatment options.
Cities with the most studies
- Houston, TX43 studies
- Baldwin Park, CA27 studies
- New York City, NY22 studies
- Seattle, WA21 studies
- Boston, MA20 studies
- Tampa, FL20 studies
- Washington, DC19 studies
- Miami, FL17 studies
- Durham, NC14 studies
- Columbus, OH14 studies
- Atlanta, GA13 studies
- Chicago, IL13 studies
- St. Louis, MO13 studies
- Nashville, TN11 studies
- Cleveland, OH11 studies
- Philadelphia, PA10 studies
- Los Angeles, CA10 studies
- Birmingham, AL10 studies
- Jacksonville, FL10 studies
- The Bronx, NY9 studies
- Buffalo, NY9 studies
- Winston-Salem, NC9 studies
- Mountain View, CA9 studies
- Pittsburgh, PA9 studies
- Baltimore, MD9 studies
- New Haven, CT8 studies
- Milwaukee, WI8 studies
- Portland, OR8 studies
- Rochester, MN8 studies
- Minneapolis, MN8 studies
- Salt Lake City, UT8 studies
- Orange, CA7 studies
- Dallas, TX7 studies
- Clifton, NJ7 studies
- Rochester, NY7 studies
- Kansas City, MO7 studies
- Memphis, TN7 studies
- Aurora, CO7 studies
- Cedar Rapids, IA7 studies
- Edison, NJ7 studies
By state
- Alabama10 studies
- Arizona11 studies
- Arkansas4 studies
- California41 studies
- Colorado9 studies
- Connecticut10 studies
- District of Columbia4 studies
- Florida32 studies
- Georgia15 studies
- Hawaii3 studies
- Idaho5 studies
- Illinois17 studies
- Indiana4 studies
- Iowa7 studies
- Kansas5 studies
- Kentucky5 studies
- Louisiana6 studies
- Maine4 studies
- Maryland23 studies
- Massachusetts22 studies
- Michigan9 studies
- Minnesota15 studies
- Mississippi3 studies
- Missouri15 studies
- Montana3 studies
- Nebraska4 studies
- New Hampshire5 studies
- New Jersey13 studies
- New Mexico4 studies
- New York38 studies
- North Carolina19 studies
- North Dakota5 studies
- Ohio22 studies
- Oklahoma4 studies
- Oregon10 studies
- Pennsylvania17 studies
- Rhode Island4 studies
- South Carolina7 studies
- Tennessee15 studies
- Texas44 studies
- Utah8 studies
- Vermont3 studies
- Virginia8 studies
- Washington22 studies
- West Virginia4 studies
- Wisconsin12 studies
Recently updated studies
Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
RecruitingObservational study
1 Day – 99 Years · All sexes · Updated Nov 13, 2026 · NCT07683104Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
RecruitingPhase 1/2
Ages 12 to 120 · All sexes · Updated Nov 13, 2026 · NCT06303193Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome
RecruitingPhase 1
Ages 21 and older · All sexes · Updated Nov 12, 2026 · NCT07737769Allogeneic iNKT Cell Therapy (agenT-797) After SCT
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07758218Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Nov 12, 2026 · NCT02115295Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
RecruitingPhase 2
Ages 4 to 80 · All sexes · Updated Nov 12, 2026 · NCT01174108Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT01311258Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT04986657Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Nov 9, 2026 · NCT06996119A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT06499285HPC Offered for PRESERVE Expansion
RecruitingObservational study
Ages 12 to 80 · All sexes · Updated Nov 6, 2026 · NCT07145411Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT05308264A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07422480At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT05969860Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06577441Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06484062Personalized NK Cell Therapy in CBT
RecruitingPhase 2
Ages 15 to 80 · All sexes · Updated Nov 2, 2026 · NCT02727803MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT05564390Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Nov 2, 2026 · NCT06904066225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Oct 30, 2026 · NCT06287944Mosaic Trial for Stem Cell Transplant Recipients
Recruiting
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06960993Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 29, 2026 · NCT06265584Study of REM-422 in Patients With AML or Higher Risk MDS
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06297941Prophylactic DLI-X for Leukemia Relapse After HCT
RecruitingPhase 1
Up to age 65 · All sexes · Updated Oct 29, 2026 · NCT07254793Cancer Experience Registry (CER) for Cancer Patients and Caregivers
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT02333604From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.